thereby supporting the program’s potential to address a broad cancer patient population. Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogeneously and ...

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

CureVac (CVAC) announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA ...

Disgraced Hollywood producer Harvey Weinstein is back in the hospital and now plans to sue New York City over “ongoing ...

Imvax, Inc. today announced an oral presentation and two poster presentations at the 2024 SNO Annual Meeting in Houston, Texas.

Umoja’s poster presentation will provide a further update on UB-VV111’s favorable safety and biodistribution profile. Details of the oral and poster presentations can be found below: Oral Presentation ...

Society for Immunotherapy of Cancer (SITC) 2023 poster. 3 Paston, et al (2024). A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced ...

Cancer Research & Immuno-Oncology Week 2022 will offer a 3-day content-rich program providing invited lectures, thought-provoking discussions, and posters to explore global developments and ...

Cyclacel Pharmaceuticals (CYCC) announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the ...

This includes an oral presentation with updated data from the Phase II IIT evaluating ZYNLONTA in combination with rituximab in patients with high-risk relapsed or refractory follicular lymphoma as ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.

In the first study, titled "The Anti-tumor Response of BPM31510 is Associated with Immune Cell Regulation in the Tumor Microenvironment," researchers showed that BPM31510 significantly increases ...